[Endothelial dysfunction and angiotensin-converting enzyme inhibitors in coronary disease].
The endothelium plays a fundamental role in the regulation of the vascular tone. It produces EDRF-NO that dilates the vessels. In endothelial dysfunction, the reduction of EDRF-NO production increases the vasoconstrive effects of endothelin-1 and angiotensin-II. The endothelial dysfunction is part of the coronary artery disease. It can be minimized by angiotensin-converting enzyme inhibitors that block the deleterious effects of angiotensin-II.
Mélon
P
P
Service de Cardiologie, Université de Liège.
D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D019332:Endothelin-1 / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000378:metabolism / Q000494:pharmacology
D000806:Angiotensin-Converting Enzyme Inhibitors; D019332:Endothelin-1; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000804:Angiotensin II; D009569:Nitric Oxide